| Diabetes Products | |||||
| Sr. No | Generic Name | Composition | Ph. Ref. | Strength | |
| 1 | Metformin Hydrochloride (Prolong Release) and Glimepiride Tablets IP | Each uncoated bilayerd tablet contains: | IP | ||
| Metformin Hydrochloride | IP | 500 mg | |||
| (Prolonged Release) | |||||
| Glimepiride | 1mg | ||||
| Excipients | q.s. | ||||
| Approved ColourUsed | |||||
| 2 | Metformin Hydrochloride (Prolong Release) and Glimepiride Tablest IP | Each uncoated bilayerd tablet contains: | IP | ||
| Metformin Hydrochloride (Prolonged Release) | IP | 500 mg | |||
| Glimepiride | |||||
| Excipients | 2mg | ||||
| Approved Colour Used | q.s. | ||||
| 3 | Glimepiride Tablets IP | Each uncoated tablet contains: | IP | ||
| Glimepiride | 1 mg | ||||
| Excipients | q.s. | ||||
| Approved Colour Used | |||||
| 4 | Glimepiride Tablets IP | Each uncoated tablet contains: | IP | ||
| Glimepiride | 2 mg | ||||
| Excipients | q.s. | ||||
| Approved Colour Used | |||||
| 5 | Metformin Hydrochloride Prolonged-Release Tablets IP | Each uncoated Prolonged- Release Tablet Contains: | |||
| Metformin Hydrochloride | |||||
| Excipients | IP | 100 mg | |||
| q.s. | |||||
| 6 | Metformin Hydrochloride Prolonged-Release Tablets IP | Each uncoated Prolonged- Release Tablet Contains: | |||
| Metformin Hydrochloride | |||||
| Excipients | IP | 500 mg | |||
| q.s. | |||||
| 7 | Metformin Hydrochloride Prolonged-Release Tablets IP | Each uncoated Prolonged- Release Tablet Contains: | |||
| Metformin Hydrochloride | |||||
| Excipients | IP | 850 mg | |||
| q.s. | |||||
| 8 | Metformin Hydrochloride Prolonged-Release Tablets IP | Each uncoated Prolonged- Release Tablet Contains: | |||
| Metformin Hydrochloride | |||||
| Excipients | IP | 1000 mg | |||
| q.s. | |||||
| 9 | Sitagliptin Phosphate Tablets IP | Each film coated Tablet contains: Sitagliptin Phosphate Monohydrate Equ. to Sitagliptin | |||
| Excipients | IP | 25 mg | |||
| Approved Colour used | q.s. | ||||
| 10 | Sitagliptin Phosphate Tablets IP | Each film coated Tablet contains: Sitagliptin Phosphate Monohydrate Equ. to Sitagliptin | |||
| Excipients | IP | 50 mg | |||
| Approved Colour used | q.s. | ||||
| 11 | Sitagliptin Phosphate Tablets IP | Each film coated Tablet contains: Sitagliptin Phosphate Monohydrate Equ. to Sitagliptin | |||
| Excipients | IP | 100 mg | |||
| Approved Colour used | q.s. | ||||
| 12 | Metformin Hydrochloride Prolonged-Release & Glimepiride Tablets IP | Each Uncoated Bilayered Tablet Contains: Glimepiride | |||
| Metformin Hydrochloride | IP | 1mg 500mg | |||
| (As Prolonged Release) Excipients | IP | ||||
| Approved colour used. | q.s. | ||||
| 13 | Metformin Hydrochloride Prolonged-Release & Glimepiride Tablets IP | Each Uncoated Bilayered Tablet Contains: Glimepiride | |||
| Metformin Hydrochloride | IP | 2mg 500mg | |||
| (As Prolonged Release) Excipients | IP | ||||
| Approved colour used. | q.s. | ||||
| 14 | Glimepiride Tablets IP | Each uncoated tablet contains: | IP | ||
| Glimepiride | 3 mg | ||||
| Excipients | q.s. | ||||
| Approved Colour Used | |||||
| 15 | Glimepiride Tablets IP | Each uncoated tablet contains: | IP | ||
| Glimepiride | 4 mg | ||||
| Excipients | q.s. | ||||
| Approved Colour Used | |||||
| 16 | Glibenclamide Tablets IP | Each uncoated tablet contains: | |||
| Glibenclamide | IP | 5 mg | |||
| Excipients | q.s. | ||||
| Approved Colour used | |||||
| 17 | Metformin Hydrochloride (ER), | Each uncoated Bilayered tablet contains: | |||
| Pioglitazone and Glimepiride Tablets | Metformin Hydrochloride | IP | 500 mg | ||
| (as Extended release) | |||||
| Pioglitazone Hydrochloride | IP | ||||
| Eq. to Pioglitazone | 15 mg | ||||
| Glimepiride | IP | 1 mg | |||
| Excipients | |||||
| Approved Colour used | q.s | ||||
| 18 | Metformin Hydrochloride (ER), | Each uncoated Bilayered tablet contains: | |||
| Pioglitazone and Glimepiride Tablets | Metformin Hydrochloride | IP | 500 mg | ||
| (as Extended release) | |||||
| Pioglitazone Hydrochloride | IP | ||||
| Eq. to Pioglitazone | 15 mg | ||||
| Glimepiride | IP | 2 mg | |||
| Excipients | |||||
| Approved Colour used | q.s | ||||
| 19 | Glimepiride and Metformin Hydrochloride (Sustained Release) Tablets IP | Each uncoated Bilayered tablet contains: | |||
| Glimepiride | IP | 1 mg | |||
| Metformin Hydrochloride | IP | 1000 mg | |||
| (as Sustained release) | |||||
| Excipients | q.s. | ||||
| Approved Colour used | q.s. | ||||
| 20 | Gliclazide & Metformin Hydrochloride Tablets | Each uncoated tablet contains: | |||
| Gliclazide | IP | 80 mg | |||
| Metformin Hydrochloride | IP | 500 mg | |||
| Excipients | q.s. | ||||
| Approved Colour used | |||||
| 21 | Gliclazide Modified – Release & Metformin Hydrochloride Extended-Release Tablets | Each uncoated bilayered tablet contains: | |||
| Gliclazide | IP | 30 mg | |||
| (in modified-release form) | |||||
| Metformin Hydrochloride | IP | 500mg | |||
| (in extended-release form) | |||||
| Excipients | q.s. | ||||
| Approved Colour used | |||||
| 22 | Gliclazide Modified – Release & Metformin Hydrochloride Extended-Release Tablets | Each uncoated bilayered tablet contains: | |||
| Gliclazide | IP | 60 mg | |||
| (in modified-release form) | |||||
| Metformin Hydrochloride | IP | 500mg | |||
| (in extended-release form) | |||||
| Excipients | q.s. | ||||
| Approved Colour used | |||||
